C
Chad Ray
Researcher at Pfizer
Publications - 22
Citations - 1335
Chad Ray is an academic researcher from Pfizer. The author has contributed to research in topics: Ex vivo & Cancer. The author has an hindex of 14, co-authored 22 publications receiving 1224 citations. Previous affiliations of Chad Ray include Eli Lilly and Company & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Fit-for-purpose method development and validation for successful biomarker measurement.
Jean W. Lee,Viswanath Devanarayan,Yu Chen Barrett,Russell Weiner,John Allinson,Scott Fountain,Stephen Keller,Ira Weinryb,Marie Green,Larry Duan,James A. Rogers,Robert Millham,Peter J. O'Brien,Jeff M. Sailstad,Masood Khan,Chad Ray,John A. Wagner +16 more
TL;DR: A practical, iterative, “fit-for-purpose” approach to biomarker method development and validation is proposed, keeping in mind the intended use of the data and the attendant regulatory requirements associated with that use, allowing increased use of biomarkers in drug development.
Journal ArticleDOI
Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum
Chad Ray,Ronald R. Bowsher,Wendell C. Smith,Viswanath Devanarayan,Mark B. Willey,John T. Brandt,Robert A. Dean +6 more
TL;DR: This multiplex immunoassay provided simultaneous measurement of circulating cytokines using 80% less patient specimen compared to traditional approaches and at a significantly decreased cost.
Journal ArticleDOI
TGF-β signalling-related markers in cancer patients with bone metastasis
José Baselga,Mace L. Rothenberg,Josep Tabernero,Joan Seoane,Thomas Daly,Ann Cleverly,Brandi Berry,Susanne Kloeker Rhoades,Chad Ray,Jeffrey Fill,Daphne L. Farrington,Lisa Anne Wallace,Jonathan M. Yingling,Michael Lahn,Carlos L. Arteaga,Michael A. Carducci +15 more
TL;DR: This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-β inhibitor, and was positively correlated with increased platelet factor 4 levels, parathyroid-related protein, von Willebrand Factor and interleukin levels.
Journal ArticleDOI
2013 White Paper on recent issues in bioanalysis: ‘hybrid’ – the best of LBA and LCMS
Lauren Stevenson,Fabio Garofolo,Binodh DeSilva,Isabelle Dumont,Suzanne Martinez,Mario Rocci,Lakshmi Amaravadi,Margarete Brudny-Kloeppel,Adrien Musuku,Brian Booth,Catherine Dicaire,Laura Wright,Laurence Mayrand-Provencher,Mike Losauro,Dominique Gouty,Mark E. Arnold,Surendra Bansal,Sherri Dudal,Dawn Dufield,Jeff Duggan,Christopher P. Evans,Eric Fluhler,Stephanie Fraser,Boris Gorovits,Sam Haidar,Roger Hayes,Stacy Ho,Richard Houghton,Rafiq Islam,Rand Jenkins,Noriko Katori,Surinder Kaur,Marian Kelley,Magnus Knutsson,Jean W. Lee,Hanlan Liu,Steve Lowes,Mark Ma,Alvydas Mikulskis,Heather Myler,Bob Nicholson,Timothy V Olah,Eric Ormsby,Shefali Patel,Vincenzo Pucci,Chad Ray,Gary Schultz,Judy Shih,Ronald Shoup,Craig Simon,An Song,João Tavares Neto,Valerie Theobald,Theingi M. Thway,Jason Wakelin-Smith,Jian Wang,Laixin Wang,Jan Welink,Emma Whale,Eric Woolf,Raymond Naxing Xu +60 more
TL;DR: This 2013 White Paper addresses important bioAnalytical issues and provides practical answers to the topics presented, discussed and agreed upon by the global bioanalytical community attending the 7th Workshop on Recent Issues in Bioanalysis.
Journal ArticleDOI
Workshop Report: Crystal City VI—Bioanalytical Method Validation for Biomarkers
TL;DR: The AAPS Crystal City VI (CC VI) Workshop in 2015 was held as the first forum for industry-FDA discussion around the general issues of biomarker measurements and specific technology strengths and weaknesses, and developed a common understanding among the industrial scientific community of the issues around biomarkers.